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Mobilized peripheral blood has become the primary source of hematopoietic stem and progenitor cells (HSPCs) for stem cell
transplantation, with a 5-day course of granulocyte colony-stimulating factor (G-CSF) as the most common regimen used for
HSPC mobilization. The CXCR4 inhibitor plerixafor is a more rapid mobilizer, yet not potent enough when used as a single agent,
thus emphasizing the need for faster acting agents with more predictable mobilization responses and fewer side effects. We
sought to improve hematopoietic stem cell transplantation by developing a new mobilization strategy in mice through combined
targeting of the chemokine receptor CXCR2 and the very late antigen 4 (VLA4) integrin. Rapid and synergistic mobilization of
HSPCs along with an enhanced recruitment of true HSCs was achieved when a CXCR2 agonist was coadministered in conjunction
with a VLA4 inhibitor. Mechanistic studies revealed involvement of CXCR2 expressed on BM stroma in addition to stimulation
of the receptor on granulocytes in the regulation of HSPC localization and egress. Given the rapid kinetics and potency of HSPC
mobilization achieved by the VLA4 inhibitor and CXCR2 agonist combination in mice compared with currently approved HSPC
mobilization methods, the combination represents an exciting potential strategy for clinical development in the future.
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Introduction
In postnatal mammals, the vast majority of hematopoietic stem
and progenitor cells (HSPCs) reside in the protective environment
of the bone marrow (BM) (1, 2). Accordingly, only very few HSPCs
can be found in the periphery, primarily in blood and spleen, during
homeostasis (3). A wide variety of stimuli has been identified that
elicits HSPC egress from the marrow, a phenomenon referred to
as mobilization (4). Despite its significance and the preclinical
discovery of various approaches to lure HSPCs into the circulation
during the past 2 decades, the armamentarium of clinical mobilization remains sparse. Thus, granulocyte colony-stimulating factor (G-CSF) is the sole agent approved for mobilization of healthy
donors, whereas in patients chemotherapy and the small molecule
antagonist of the chemokine receptor CXCR4, AMD3100 (Plerixafor), are approved in conjunction with G-CSF (5).
Limitations of currently available clinical regimens provide the
rationale for the ongoing search for alternative mobilization strategies. Importantly, all approaches described to date target at least
1 of the 2 major axes mediating HSPC retention: the chemokine
receptor CXCR4 or the integrin very late antigen 4 (VLA4) (4, 6, 7).
Inhibition of the interaction between CXCR4 and its chief ligand
CXCL12 has been extensively studied by us and others (8–13). By
contrast, targeting of VLA4 and use thereof to release HSPCs from
the BM has been explored considerably less intensively due to lack
of suitable small molecule compounds with favorable pharmacologic properties (7, 14).
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The chemokine receptor CXCR2 is a critical regulator of
neutrophil chemotaxis (15). Interestingly, stimulation of CXCR2
signaling (e.g., with its ligands CXCL1, -2, or -8) has been demonstrated to result in rapid HSPC mobilization from the BM even
though the receptor is not expressed on HSPCs themselves (16–
20). The mechanism of HSPC egress after CXCR2 stimulation
remains controversial.
In this study, we explored the potential of combined targeting of VLA4 and CXCR2 signaling as a novel strategy to mobilize
HSPCs. In addition to being associated with a rapid and remarkably
synergistic HSPC release, administration of a VLA4 antagonist in
conjunction with a CXCR2 ligand targeted very primitive, serially
repopulating HSPCs with high efficiency. Our observations challenge the notion of limited potential of fast-acting mobilizing agents
and are particularly relevant in the context of the ongoing debate
about the vascular versus endosteal localization of stem cells (21–23).
Moreover, unexpectedly, stromal cells were found to be targeted
by CXCR2 stimulation along with neutrophils. This contribution
of both stromal and neutrophilic CXCR2 to the regulation of HSPC
localization underlies the intricate interplay between nonhematopoietic and mature hematopoietic cells for HSPC maintenance.

Results
Combined targeting of VLA4 and CXCR2 results in augmented HSPC
recruitment. We assessed the mobilization efficiency of a VLA4
antagonist alone compared with a CXCR2 agonist alone, as well
as their combined effect in vivo. The previously described smallmolecule VLA4 inhibitor firategrast (24, 25) along with the naturally occurring truncated form of the CXCR2 ligand Gro-ȕ (tGro-ȕ)
(26, 27) were used in the initial experiment. As shown in Figure 1,
combined treatment with both agents resulted in increased numbers of circulating WBCs and CFU-Cs of up to 3- and 10-fold,
respectively (Figure 1, A and B). To circumvent the shortcomings of
VLA4-targeting compounds hitherto tested as mobilizing agents,
we selected a series of VLA4 antagonists that had been developed
based on the structure of the well-known VLA4 inhibitors BIO5192
(28) and firategrast (24, 25). These compounds (CWHM-822,
823, 824, 825, and 842; Figure 1C) were synthesized as previously
described (29–34). Properties of the inhibitors were assessed using
a colorimetric, cell-free, solid-phase receptor binding assay (SPRA;
Supplemental Table 1; supplemental material available online
with this article; https://doi.org/10.1172/JCI124738DS1) as well
as a flow cytometry–based soluble VCAM1 binding assay (Figure
1D). CWHM-823, -824, and -842 showed superior binding affinity to VLA4 compared with firategrast (Figure 1D). CWHM-822
and -823 had an improved water solubility compared with both
BIO5192 and firategrast (Supplemental Table 1).
We next tested whether the synergism between VLA4 inhibition and CXCR2 stimulation was a compound class as opposed
to a compound-specific effect. Therefore, mobilization with
BIO5192 and firategrast was tested alongside the new compounds,
CWHM-823 and -842. All 4 inhibitors mobilized HPSCs by themselves, whereas the mobilization response was enhanced up to
3- to 10-fold when combined with tGro-ȕ (Figure 1E), suggesting
a compound class–specific effect. Firategrast-related CWHM-823
outperformed the BIO5192-related CWHM-842 in vivo and was
therefore selected for the majority of our subsequent analyses.
2746
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Optimal pharmacokinetics and pharmacodynamics were determined to be associated with subcutaneous administration of the
CWHM-823 plus tGro-ȕ mixture (Supplemental Figure 1, A and
B). Time and dose-response analysis revealed no increase in mobilization between 3 mg/kg and 15 mg/kg of CWHM-823, whereas
peak mobilization was reached approximately 30 minutes after
the injection (Supplemental Figure 1C).
Complementary to the testing of different VLA4 inhibitors,
stimulation with tGro-ȕ (CXCL2) was compared with that of the
alternative CXCR2 ligands CXCL1 (Gro-Į) and CXCL8 (IL-8).
Again, all 3 agonists induced HSPC mobilization when given alone
as well as in combination with CWHM-823 (Figure 1F). To control for specificity of the observed effects, CXCR2-KO mice were
included. As expected, CXCR2 ligands alone did not induce mobilization in CXCR2-KO mice. Mobilization with the VLA4 antagonist
was higher in absolute numbers yet qualitatively unchanged considering the higher baseline levels of circulating CFU-C (930 CFU-C/
ml [BALB/cJ CXCR2-KO] versus 300 CFU/ml [BALB/cJ WT] at
baseline, and 3800 CFU-C/ml [BALB/cJ CXCR2-KO]versus 1300
CFU-C/ml [BALB/cJ WT] mobilized with CWHM-823). Surprisingly, a decrease in mobilization with CWHM-823 was observed in
CXCR2-KO mice when CXCR2 ligands were coadministered with
the VLA4 antagonist. One possible explanation for this is that the
bioavailability of CWHM-823 is reduced upon administration in
conjunction with the chemokine as compared with its administration alone (Supplemental Figure 1B). Lack of specificity for the target
receptor CXCR2 appears unlikely: in our comprehensive screening
of tGro-ȕ against a panel of 348 different G protein–coupled receptors, no cross-reactivity of the chemokine with any receptors other
than CXCR2 was found (Supplemental Table 2).
Properties of mobilized cells. Having established that VLA4 inhibition combined with CXCR2 stimulation achieves superior CFU-C
mobilization, we compared the repopulating capacity of the grafts
mobilized with this new regimen, the single agents, or G-CSF (Figure 2A). For both VLA4 antagonists tested (firategrast and CWHM823), a significantly increased blood graft–derived contribution in
the primary recipients was detected when each antagonist was combined with tGro-ȕ compared with engraftment from blood mobilized by either of the VLA4 antagonists or tGro-ȕ alone (Figure 2B).
More importantly, despite higher numbers of CFU-Cs mobilized by
G-CSF (Supplemental Figure 2 and data not shown), the concentration of repopulating units in the blood of mice mobilized with VLA4
antagonist plus tGro-ȕ was equal to that of G-CSF. Analysis of secondary recipients (i.e., evidence of serially repopulating units) confirmed virtually identical mobilization potency within the immature
HSC fraction for G-CSF and VLA4 antagonist plus tGro-ȕ (Figure
2C). Moreover, in a model of diabetes-associated poor mobilization (10, 35, 36) generated by exposure of mice to the pancreas
toxic agent streptozotocin, mobilization was better preserved with
VLA4 antagonist plus tGro-ȕ combination as compared with G-CSF
(7200 CFU-C/ml in diabetic compared with 22,200 CFU-C/ml in
healthy mice with G-CSF; 9000 compared with 6350 CFU-C/ml
with CWHM-823 plus tGro-ȕ, Supplemental Figure 2).
We then performed gene expression profiling of differentially
mobilized HSPCs. LSK cells isolated from the blood of mice treated
with AMD3100 (1 hour), G-CSF (5 days), or CWHM-823 plus
tGro-ȕ (30 minutes) along with LSK cells from BM of untreated
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Figure 1. Targeting VLA4 and CXCR2 to mobilize HSPCs. (A–B) DBA2/J mice were treated with the VLA4 inhibitor firategrast (100 mg/kg, i.v.), the CXCR2 ligand
tGro-ȕ (2.5 mg/kg, s.c.) or both agents immediately after each other. Blood was analyzed for WBCs (A) and CFU-Cs (B). Data are mean ± SEM, n = 5. ***P < 0.001,
**P < 0.01, compared with firategrast alone/compared with tGro-ȕ alone. (C) Molecular structures. (D) G2-ALL cells were treated in duplicate with the VLA4 inhibitors
shown in C. Percent inhibition of VCAM1 binding as compared with untreated samples. Data are mean ± SEM of a single experiment representative of 3 experiments.
(E) DBA2/J mice were injected with tGro-ȕ (2.5 mg/kg, s.c.), a VLA4 antagonist (3 mg/kg, i.v., for BIO5192, CWHM-823, and -842; 100 mg/kg, i.v., for firategrast), or
their combination. Controls received vehicle only. Numbers of circulating CFU-Cs and LSK cells were analyzed 0.5 hours after the injection(s). Data are mean ± SEM,
n = 8–10. ***P < 0.001, **P < 0.01, *P < 0.01, compared with tGro-ȕ alone/VLA4 antagonist alone. (F) HSPC mobilization in CXCR2-KO mice using the CXCR2 ligands
CXCL1, CXCL2 (tGro-ȕ), and CXCL8 and the VLA4 antagonist CWHM-823 as well as their combinations was compared with that in WT BALB/cJ. Blood CFU-C numbers
were analyzed at baseline, 15 minutes after injection of CXCR2 ligands (s.c., 1 mg/kg CXCL1 and CXCL8, 2 mg/kg tGro-ȕ), 1 hour after injection of CWHM-823 (s.c., 3
mg/kg), and 30 minutes after the combined treatment (s.c. injection of each ligand together with CWHM-823 at same doses as single treatments). Data are mean
± SEM, n = 4–26 in mobilized groups, n = 51–78 in baseline groups. ***P < 0.001, compared with CXCR2 agonist alone/compared with CWHM-823 alone. Statistical
comparisons were made using linear mixed models in A and B and ANOVA in all others, followed by step-down Bonferroni’s adjustment for multiple comparisons.

mice were examined using microarray analysis. A high degree
of similarity between the analyzed LSK types was found, with
AMD3100-mobilized LSK cells being the only group clustering
somewhat separately from the other 3 using principal component analysis (PCA, Figure 2D). In comparison to BM, LSK cells
mobilized by CWHM-823 plus tGro-ȕ had only 45 genes with
significantly different expression levels (Supplemental Table 3).

CWHM-823 plus tGro-ȕ versus G-CSF had only 53 such genes
(Supplemental Table 4). By contrast, 694 genes were significantly
up- or downregulated between AMD3100 and CWHM-823 plus
tGro-ȕ–mobilized LSK cells despite their very similar kinetics
of mobilization (Supplemental Table 5). The close relationship
between CWHM-823 plus tGro-ȕ–mobilized LSK cells, BMresident LSK cells, and G-CSF LSK cells was further evident upon
jci.org
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Figure 2. Properties of mobilized HSPCs. (A) Schema for analyzing competitive repopulating capacity. Blood (10 ȝl) from CD45.1+ donors (BALB/cJ, n = 2–3)
mobilized with G-CSF (9 doses every 12 hours, 100 ȝg/kg per dose), tGro-ȕ (2.5
mg/kg, 15 minutes after s.c. injection), VLA4 antagonist firategrast (100 mg/
kg, 1 hour after s.c. injection), and CWHM-823 (3 mg/kg, 1 hour after s.c. injection), or the combination of tGro-ȕ and VLA4 antagonist (dosed as indicated
for single injections, 30 minutes after simultaneous injection) was mixed with
CD45.2+ competitor BM cells (BALB/cJ, n = 2 donors, 2.5 × 105 cells per recipient)
and transplanted into lethally irradiated primary CD45.2+ hosts (BALB/cJ, n =
8–10 recipients). (B) Percent CD45.1+ donor cells within the CD45+CD3– compartment of blood was evaluated 20 weeks after transplantation. Data are mean ±
SEM, n = 8–10. ***P < 0.001 compared with VLA4 antagonist alone/compared
with tGro-ȕ alone. (C) BM from the primary recipients was harvested, pooled,
and transplanted into lethally irradiated secondary recipients (CD45.2+ BALB/
cJ, 2.5 × 106 per recipient). The percentage of donor-derived cells in the blood of
secondary recipients 18 weeks after transplantation is shown. Data are mean
± SEM, n = 5 and are not significantly different. *P < 0.05. (D–F) LSK cells were
sorted from the blood of DBA/2J mice mobilized with G-CSF (9 doses every 12
hours, 100 ȝg/kg per dose, n = 3), AMD3100 (5 mg/kg, 1 hour after injection,
n = 3), or CWHM-823 plus tGro-ȕ (3 mg/kg and 2.5 mg/kg, 30 minutes after
simultaneous s.c. injection, n = 3). LSK cells from steady-state BM were
included as control. Total RNA from sorted cells was subjected to microarray
expression analysis. (D) Principal component analysis (PCA) of mRNA expression of different LSK species. (E) Corresponding hierarchical clustering map.
(F) Normalized expression values for the genes Nr4A1-3. Each source/treatment group included n = 3 samples (pooled from up to 6 donors). Statistical
comparisons were made using ANOVA, followed by step-down Bonferroni’s
adjustment for multiple comparisons.

clustering of the top 1000 differentially expressed genes, which
demonstrated clear separation of the AMD3100-mobilized LSK
cells (Figure 2E).
Among the genes significantly enriched in CWHM-823 plus
tGro-ȕ–mobilized LSK cells, the transcription factors Nr4A1-3
were identified (Figure 2F). Members of this nuclear receptor
family have previously been shown to specify a population of
myeloid-biased long-term repopulating HSCs (37). This is consistent with a relative enrichment of the latter within CWHM-823
plus tGro-ȕ–targeted HSPCs. Distinct properties of CWHM-823
plus tGro-ȕ LSK cells were further confirmed when cell cycle status of differentially mobilized HSPCs was assessed (Supplemental
Figure 3). LSK cells mobilized with CWHM-823 were predominantly quiescent with more than 70% found in the G0 phase and
approximately 25% and 3% found in G1 and G2/S/M phases of
the cell cycle, respectively. A much lower proportion of tGro-ȕ–
mobilized LSKs were not cycling (approximately 50% in G0) and
virtually no cells were in G2/S/M phase. In contrast, more than
half of the LSK cells from CWHM-823 plus tGro-ȕ–mobilized
blood were actively cycling and 5% was found in the G2/S/M
phase. Thus, LSK cells mobilized with the combination of VLA4
inhibition and CXCR2 stimulation do not simply represent a mix
of those mobilized by single agents. Given the rapid kinetics of
mobilization by these agents when administered alone and in
combination, the discrepancies between the cell cycle distribution
imply preferential targeting of distinct LSK species rather than
changes induced upon exposure to the different agents.
Cellular mechanism of mobilization. We sought to determine
which of the 2 events, CXCR2 stimulation or VLA4 inhibition,
needs to occur first and is therefore the priming event for the subsequent response to the second stimulus. Pretreatment with the

VLA4 antagonist (CWHM-823, 45 minutes prior to tGro-ȕ administration) did not alter subsequent tGro-ȕ–induced mobilization
(Figure 3A). In contrast, albeit lower than when both compounds
were given simultaneously, significantly elevated numbers of circulating CFU-Cs were detected in CWHM-823–mobilized mice
that had been pretreated with tGro-ȕ as compared with PBS. These
findings pointed toward CXCR2 targeting as the priming event.
Within the hematopoietic compartment, CXCR2 expression
was detected almost exclusively in granulocytes, and specifically
HSCs themselves were CXCR2-negative (Supplemental Figure
4). Therefore, as expected, when granulocytes were depleted
from the circulation (Figure 3, B and C), mobilization responses
to tGro-ȕ alone as well as to the combination of CWHM-823 plus
tGro-ȕ were completely blunted (Figure 3D).
In order to distinguish between hematopoietic-intrinsic versus
nonhematopoietic contributions for mobilization with CWHM823 plus tGro-ȕ, chimeric animals were generated by transplanting CXCR2-KO or WT BM cells into WT recipients and vice versa,
WT cells into CXCR2-KO or WT recipients (Figure 4A). Following reconstitution, mice were mobilized with CWHM-823 alone,
tGro-ȕ alone, or the combination. As expected, mobilization with
the VLA4 antagonist alone was similar in both hematopoietic and
stromal CXCR2 knockouts (Figure 4B). No HSPC mobilization
with tGro-ȕ alone was observed in WT recipients reconstituted
with CXCR2-KO BM (Figure 4C, first and second bars from left).
Surprisingly, CXCR2-KO recipients engrafted with the WT BM also
demonstrated attenuated mobilization (Figure 4C, fifth and sixth
bars from left), indicating an additional contribution of nonhematopoietic (stromal) CXCR2 to the tGro-ȕ–induced HSPC egress.
Moreover, the combination of CWHM-823 and tGro-ȕ mobilized
HSPCs with almost equal potency in WT recipients of CXCR2KO and WT BM (Figure 4D, comparing second and fourth bars
from left). Mobilization of similar magnitude was also detected
in CXCR2-KO and WT recipients reconstituted with WT BM. Stimulation of either hematopoietic or stromal CXCR2 was therefore
sufficient to elicit synergistic mobilization when combined with
inhibition of VLA4 signaling.
Expression and functional role of CXCR2 in endothelial cells
(ECs) has been described (38, 39). Our previous studies indicated
the absence of CXCR2 expression in CXCL12-abundant reticular cells (CARs, another major cellular player involved in HSPC
retention) (40, 41). We therefore tested whether CXCR2 ablation
restricted to ECs would lead to changes in mobilization responses.
As shown in Figure 4E, mobilization with all 3 regimens (CWHM823, tGro-ȕ, and CWHM-823 plus tGro-ȕ) was decreased in
CXCR2 EC-KO recipients compared with the control group. Most
pronounced was the effect observed with tGro-ȕ alone.
Role of cellular adhesion. Our studies suggested that stimulation of CXCR2 on either granulocytes or stroma was sufficient
to recruit as many HSPCs into the circulation as when the target
receptor was present in both compartments (Figure 4). This led
us to investigate the role of adhesive cross-stimulatory interaction
between neutrophils and stroma, likely initiated through exposure
to the chemokine. Beta 2 integrins LFA1 (ITGAL/ITGB2, CD11a/
CD18) and Mac1 (ITGAM/ITGB2, CD11b/CD18) are well-known
crucial mediators of neutrophil adhesion to vasculature (42, 43).
Both have been shown to become activated after CXCR2 stimulajci.org
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Figure 3. Granulocytes are indispensable for tGro-induced mobilization. (A) Effect of different sequences of injection. Two groups of BALB/cJ mice received
pretreatment with PBS or tGro-ȕ (2.5 mg/kg, s.c.) 15 minutes prior to the injection of CWHM-823 (3 mg/kg, s.c.). Accordingly, 2 other groups were pretreated
with PBS or the VLA4 antagonist (3 mg/kg CWHM-823, s.c.) 45 minutes prior to tGro-ȕ (2.5 mg/kg, s.c.) injection. A fifth group received a simultaneous injection
of CWHM-823 plus tGro-ȕ at the indicated doses. At 15 and 60 minutes after the administration of the second compound (or the simultaneous injection in the
control group), circulating CFU-C numbers were measured. Each bar is mean ± SEM, n = 4–5. ***P < 0.001, **P < 0.01, *P < 0.05. (B–D) For transient depletion
of blood neutrophils, mice were pretreated with an anti-Gr1 antibody in vivo (200 ȝg/mouse, i.v.) 36 hours prior to mobilization with tGro-ȕ (2.5 mg/kg, s.c., time
point 15 minutes), CWHM-823 (3.0 mg/kg, s.c., time point 60 minutes), or the combined agents (doses same as for separate treatments, time point 30 minutes).
Nonmobilized mice were used as controls (baseline). Moreover, all 4 conditions were analyzed in cohorts that had been pretreated with a control antibody (200
ȝg/mouse, i.v.). (B) Representative scatter plot analyses of unmobilized blood using flow cytometry, with granulocytes virtually absent in anti-Gr1–treated mice.
(C–D) Numbers of circulating neutrophils (C) and CFU-Cs (D). Each bar is mean ± SEM, n = 7–9. ***P < 0.001, **P < 0.01. Statistical comparisons were made using
ANOVA, followed by step-down Bonferroni’s adjustment for multiple comparisons. Logarithm transformation was performed for the data in C and D.

tion (44–46) and have been previously implicated in CXCR2- and
G-CSF–triggered mobilization (19, 47, 48).
At baseline, no significant hematological changes were found
in mice lacking LFA1 (CD11a-KO) or Mac1 (CD11b-KO) except
for a slight increase in circulating neutrophils in CD11a knockouts (Figure 5, A–C). Mobilization of CFU-C with CWHM-823
was approximately doubled in CD11a- or CD11b-deficient mice,
whereas both strains’ response to tGro-ȕ alone was the same as in
2750
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WT mice, despite a dramatic neutrophilia induced in the CD11aKO mice in response to tGro-ȕ (Figure 5B). The response to the
combination treatment was significantly attenuated (Figure 5C).
Role of proteases. Considering the fact that CXCR2 is not
expressed on the surface of the HSPCs themselves, we next
addressed the question of the molecular crosstalk initiated by
CXCR2 stimulation and how it enables HSPC egress. Previous
reports aiming to elucidate the mechanism of tGro-ȕ and AMD3100
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Figure 4. CXCR2 expression in both the hematopoietic and nonhematopoietic (stromal) compartment contributes to tGro-induced mobilization. (A) Hematopoietic-specific CXCR2-KO mice were generated by transplanting lethally irradiated CD45.1+ recipients (BALB/cJ) with CD45.2+ BM cells isolated from CXCR2-KO
mice (BALB/c, 1 × 106 cells per recipient, n = 3 BM donor mice). A control group was reconstituted with CD45.2+ WT BM cells (BALB/c, 1 × 106 cells per recipient,
n = 3 BM donor mice). Stromal-specific knockouts were generated by transplanting CD45.1+ WT BM cells (BALB/cJ, 1 × 106 cells per recipient, n = 3 BM donors) into
CXCR2-KO mice (CD45.2+). In the corresponding control group, WT CD45.2+ recipients were transplanted with the WT CD45.1+ BM graft. (B–D) Three months after
transplantation, circulating HSPC numbers (Lin-kit+ cells) were assessed in the different recipients at baseline and following mobilization with CWHM-823 alone
(3 mg/kg, 1 hour after s.c. injection, B), tGro-ȕ alone (2.5 mg/kg, 15 minutes after s.c. injection, C), and both agents combined (dosed as indicated for separate
treatments, 30 minutes after simultaneous s.c. injection, D). Each bar is mean ± SEM, n = 4–5. ***P < 0.001, **P < 0.01, *P < 0.05. (E) Lethally irradiated CXCR2fl/fl
Cdh5Cre+ hosts (C57BL/6 background, CD45.2+) were reconstituted with syngeneic WT CD45.1+ BM (3 × 106 cells per recipient) to generate EC-specific knockout
recipients. In the control group, CXCR2fl/+Cre+ and CXCR2+/+ Cre+ mice were used as recipients. Three months after transplantation, circulating HSPC (CFU-C)
numbers were quantified at baseline and following mobilization with CWHM-823 alone (3 mg/kg, 1 hour after s.c. injection), tGro-ȕ alone (2.5 mg/kg, 15 minutes
after s.c. injection), and both agents combined (dosed as indicated for separate treatment, 30 minutes after simultaneous s.c. injection). Each bar is mean ± SEM,
n = 6. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni’s adjustment for multiple comparisons. Logarithm transformation
was performed for the data in D and E.

plus tGro-ȕ–induced HSPC release suggested critical involvement
of the matrix metalloprotease 9 (MMP9) (49–52). Therefore, we
compared mobilization with the combination of CWHM-823 plus
tGro-ȕ against AMD3100 plus tGro-ȕ as well as single agent treatments in MMP9-KO mice on both FVB and C57BL/6 (B6) background (Supplemental Figure 5, A and B). In addition, a pharma-

cologic model in the form of a broad-spectrum MMP inhibitor,
batimastat, was employed (Supplemental Figure 5C). Baseline
circulating HSPC numbers or AMD3100-induced mobilization
were not affected by the genetic MMP9 deficiency or by the MMP
blockade. CWHM-823–induced mobilization was equally potent in
FVB WT and FVB MMP9-KO mice and was not affected by batijci.org
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of MMP9 in CWHM-823 plus tGro-ȕ–associated augmented mobilization. Rather, they suggest differences in the mechanism underlying mobilization induced by combining CXCR2 stimulation and
VLA4 blockade compared with CXCR2 activation in conjunction
with CXCR4 blockade.

Discussion

Figure 5. Role of cell adhesion on mobilization. (A–C) Mobilization in LFA1
(CD11a) and Mac1 (CD11b) knockout mice. CD11a-KO and CD11b-KO as well as
WT C57BL/6J mice received an injection of PBS, tGro-ȕ (2.5 mg/kg, s.c., time
point 15 minutes), CWHM-823 (3.0 mg/kg, s.c., time point 60 minutes), or the
2 agents combined (dosed the same as for separate treatments, time point
30 minutes). Mobilization of WBCs (A), neutrophils (NEs) (B), and CFU-Cs (C)
was assessed. Each bar is mean ± SEM, n = 4–8. ***P < 0.001, **P < 0.01, *P <
0.05. Statistical comparisons were made using ANOVA, followed by step-down
Bonferroni’s adjustment for multiple comparisons.

mastat. However, mobilization was stronger in B6 MMP9-KO mice
than in their WT counterparts. Conversely, tGro-ȕ– and AMD3100
plus tGro-ȕ–induced mobilization was significantly reduced in FVB
MMP9-KO mice or following MMP inhibitor treatment, but it was
not altered in B6 MMP9-KO mice. Interestingly, the combination
of CWHM-823 plus tGro-ȕ mobilized with equal efficiency in both
knockout strains relative to WT control mice, whereas mobilization
was slightly, but not significantly, reduced in mice pretreated with
batimastat. Taken together, these data do not support a clear role
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In the current study, a novel mobilization strategy, CXCR2 stimulation combined with inhibition of the VLA4 integrin, was investigated and found to result in a rapid, synergistic, and highly efficient recruitment of HSPCs into the circulation. Implementation
of VLA4 antagonists with improved properties allowed for comprehensive testing and optimization of mobilization achieved through
VLA4 targeting. This revealed VLA4 as a promising target associated with mobilization of a clinically relevant magnitude. Compared with mobilization with G-CSF, long-term serially repopulating HSCs were relatively more strongly enriched in VLA4 inhibitor
plus CXCR2 agonist–mobilized grafts than clonogenic cells without
long-term repopulating capacity, indicating preferential targeting of
a very immature HSPC fraction. Given how brisk the mobilization
occurred and assuming BM sinusoids as the exit route for HSCs,
our findings support the notion of a close proximity of the mobilization-sensitive HSCs to BM sinusoids. Moreover, the numbers of
rapidly mobilizable HSCs markedly exceeded previous estimates.
Furthermore, we found an unexpected contribution of stromal
(endothelial) CXCR2 to the mobilization induced by tGro-ȕ alone
as well as by VLA4 antagonist plus tGro-ȕ, hinting at a previously
unsuspected crosstalk between granulocytes and stroma as a master regulator of HSPC localization and egress.
The cytokine G-CSF and chemotherapy-triggered myeloid
rebound, the 2 commonly utilized clinical mobilization regimens, are
comprised of 2 partly overlapping steps, proliferation and the actual
release of the HSPCs from the BM (53, 54). Although not necessary
nor sufficient for mobilization per se, proliferation (and therefore
expansion) of HSPCs clearly contributes to the magnitude of G-CSF
and chemotherapy-induced HSPC mobilization (55). In addition
to the obvious increase in numbers, HSPC localization has been
reported to change over the course of proliferation, favoring closer
proximity to the vessels, which in turn facilitates BM exit (56, 57). In
comparison, the rapid kinetics of mobilization with VLA4 antagonist plus tGro-ȕ (peak reached within 15–30 minutes of s.c. injection)
would not allow for cell division to occur prior to the HSPC release
from the BM. Therefore, the relative enrichment for primitive, serially repopulating units in the VLA4 antagonist plus tGro-ȕ–mobilized
blood grafts likely reflects their preferential targeting and a preferential vascular (sinusoidal) localization. Compared with G-CSF
and chemotherapy, much less severe alterations in the BM composition in the course of VLA4 antagonist plus tGro-ȕ–mediated mobilization are to be expected, which is particularly important in light of
the very similar potency.
Mature hematopoietic cells contained in the transplant have
been shown to directly influence HSPC engraftment. For example, the presence of regulatory T cells was demonstrated to ensure
HSPC survival and colonization of the host BM (58). Also, bystander effects of the myeloid compartment, granulocytes in particular,
for the establishment of the niche following irradiation/transplantation were recently described (59). Thus, granulocyte-derived
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Figure 6. Proposed mechanisms for targeting CXCR2 and VLA4 to mobilize hematopoietic stem cells. (A–D) Schematic presentation of HSPC and mature hematopoietic cell (NE) localization in the BM relative to the vasculature. Adhesive interactions and cellular distribution are shown under steady state (A) compared with
following mobilization with a VLA4 antagonist (B), CXCR2 agonist (C), and the combination of the 2 strategies (D). For a detailed description see the Discussion.

TNF-Į was shown to facilitate vasculogenesis, a critical step during
regeneration. Given the high percentage as well as the direct stimulation of neutrophils in VLA4 antagonist plus tGro-ȕ–mobilized
(and also G-CSF–mobilized) blood specimens, it is conceivable
that granulocyte-derived factors contribute to the superior performance of the corresponding grafts. While not excluding this possibility, the results of our LSK gene expression profiling further imply
inherent differences in the profile and composition of the differentially mobilized versus BM resident HSPC populations themselves.
In line with the idea that differences within the HSPC fraction (i.e., a
higher proportion of more immature, serially repopulating cells) are
primarily responsible for the observed graft fitness, LSK SLAM cells
purified from AMD3100 plus tGro-ȕ–mobilized blood (a regimen
very similar to ours) were found to outperform those isolated from
G-CSF–treated blood donors when both were tested head-to-head
in a competitive transplant assay against BM cells (52).
Neutrophils have been demonstrated to be indispensable for
IL-8–induced (and G-CSF–induced) mobilization (51, 60). Therefore, our observation of a significant reduction of tGro-ȕ as well as
CWHM-823 plus tGro-ȕ–associated mobilization in the context
of granulocyte deficiency was in line with expectations. By contrast, the subsequent findings that nonhematopoietic CXCR2expressing cells coregulate HSPC egress triggered by tGro-ȕ alone
and that the presence of the receptor in either one of the com-

partments, stroma or hematopoietic cells, was in fact sufficient to
elicit HSPC egress when the combination of CWHM-823 plus
tGro-ȕ was used, were very much surprising. Thus, while the presence of granulocytes was necessary for both, tGro-ȕ and CWHM823 plus tGro-ȕ–induced mobilization, lack of CXCR2 expression
on their surface seemed, to a large extent, to be compensated for
in the case of CWHM-823 plus tGro-ȕ treatment, as long as the
stromal CXCR2 was present.
Relevant for the interactions between HSPC and neutrophils,
a role of CXCR2 expression in endothelia has been increasingly
recognized. Accordingly, CXCR2 expression in ECs of the lung
vessels and its involvement in controlling neutrophil passage from
the circulation into the lung parenchyma have been described
(38). CXCR2 signaling has also been shown to critically mediate
EC proliferation and therefore vascular repair after transplantation (39). Moreover, involvement of the zebrafish CXCR2 ortholog
CXCR1 in the hematopoietic stem cell niche remodeling during
embryogenesis has been demonstrated (61). Our findings along
with the results of a companion study (unpublished observations)
imply an additional, immediate role of endothelial CXCR2 in the regulation of HSPC retention versus egress.
Significant controversy surrounds the role of matrix metalloproteases in general and MMP9 in particular for mobilization
regimens involving neutrophil stimulation such as tGro-ȕ, IL-8, or
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G-CSF. In a recent study by Hoggatt et al. describing a mobilization
approach similar to ours (AMD3100 plus tGro-ȕ, ref. 52) the authors
reported a contribution of MMP9 activity to the synergistic mobilization response in mice. Moreover, a correlation between mobilization efficiency in healthy G-CSF donors and activity of the MMP9
inhibitor TIMP1 was described. In our analysis, a trend toward
a more pronounced contribution of MMP9 during HSPC egress
induced by AMD3100 plus tGro-ȕ as compared with CWHM-823
plus tGro-ȕ was observed. However, a requirement for intact MMP9
for a tGro-ȕ–based regimen could not be corroborated.
The differences in the magnitude and kinetics of HSPC egress
associated with the different regimens analyzed in this study, as
well as the distinct properties of cells mobilized with VLA4 antagonists alone, versus tGro-ȕ alone, versus VLA4 antagonist plus
tGro-ȕ, can be interpreted as a result of targeting distinct HSPC
subsets (Figure 6A–D). Thus, based on their performance in the
competitive transplantation setting (Figure 2, A–C), more mature
progenitor cells are primarily mobilized with a VLA4 antagonist alone (Figure 6B). Expression of the beta 2 integrins LFA1
and Mac1 on human and murine hematopoietic progenitor cells
(HPCs) but not stem cells has been demonstrated (48, 62). Hence,
although not markedly dislodging stem cells when blocked individually, inhibition of LFA1 or Mac1 in conjunction with VLA4
blockade resulted in enhanced HPC mobilization. Consistent with
the direct mode of action of VLA4 antagonists (4, 63), loss of granulocytes did not affect VLA4 inhibitor–induced HSPC egress.
Peak mobilization after tGro-ȕ treatment is remarkably fast.
Activation of CXCR2 signaling in ECs has been reported to lead to
EC contraction (64, 65) and weakening of intercellular junctions
(66, 67). In accordance with these reports, we detected increased
permeability of vascular cells after CXCR2 stimulation in vivo and
in vitro (unpublished observations). Increased vascular leakiness has
also been found in the BM of tGro-ȕ–treated mice (52) and is likely a
major contributor to the brisk kinetics of tGro-ȕ–triggered HSPC emigration (Figure 6C). Moreover, though not addressed in our analysis
directly, an involvement of the complement cascade, a key orchestrator of pharmacologically and pathologically induced HSPC release
from the BM (68, 69), and the associated release of anaphylatoxins
might have facilitated increased vascular permeability. The latter are
further known to stimulate the release of the lipolytic enzyme phospholipase C ȕ2 (PLCB2), which in turn disrupts the lipid raft formation needed for optimal signaling via VLA4 and CXCR4 (68, 70).
Adhesive interactions and cross-stimulation between CXCR2expressing granulocytes and endothelia are critical for the
increased permeability and likely also for the subsequent cell-cell
contact or soluble mediator-enabled HSPC release in the context of mobilization with tGro-ȕ alone. However, in contrast to
the reported requirement of LFA1 for IL-8–induced mobilization
(19), neither deficiency for LFA1 nor for Mac1 enhanced tGro-ȕ–
mediated HSPC egress. Loss of one beta 2 integrin was possibly
compensated for by the presence of the other, along with other
integrins. With regard to the HSPC population targeted, the transplant data suggested predominant mobilization of progenitor cells
with tGro-ȕ, as was the case with VLA4 antagonist alone. Hence,
elevated vascular permeability and reduced retention induced by
tGro-ȕ alone are not sufficient to release the HSCs from their protective BM environment.
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Finally, when tGro-ȕ is combined with a second stimulus in
the form of VLA4 inhibition, in addition to the reciprocal stimulation of CXCR2-expressing cells, the associated changes in permeability and cell contact and/or soluble mediator decreased
HSPC retention, which is further hit by lack of VLA4 signaling
(Figure 6D). As demonstrated by the results of the serial competitive transplantation analysis, this combination of events
indeed recruited with high efficiency highly engraftable, true
HSCs into the circulation. Cross-stimulation of tGro-ȕ targeted
cells that were dependent on integrin interactions, and blockade
of both VLA4 and either LFA1 or Mac1 appears to disturb rolling and adhesion and therefore proximity of CXCR2-expressing
cells to an extent that cannot be compensated, unlike when
tGro-ȕ is given alone. This concept could explain the relatively
less efficient mobilization with VLA4 antagonist plus tGro-ȕ in
mice lacking beta 2 integrins.
In summary, we show that simultaneous administration of
CXCR2 agonists in conjunction with VLA4 small-molecule inhibitors results in rapid and robust mobilization of HPCs and HSCs.
A contribution of hematopoietic (neutrophils) and nonhematopoietic (endothelial) CXCR2 to the mobilization response was found.
Grafts mobilized with the VLA4 inhibitor plus tGro-ȕ combination
exhibited serial repopulating capacity. Given several advantages
of this combination over currently approved HSPC mobilization
methods, it represents an exciting potential strategy for clinical
development in the future. We are continuing to optimize the
pharmacokinetic and pharmacodynamic properties of the VLA4
inhibitors to enable future large-animal efficacy and toxicology
studies in nonhuman primates, which are currently underway.
Further, our data support the proposed perisinusoidal localization
of very primitive (true) HSCs and will also serve as a tool to learn
more about the interplay between mature hematopoietic cells,
nonhematopoietic stroma, and stem cells.

Methods
Mice
Male 6- to 12-week-old WT BALB/cJ (CD45.2+), BALB/cByJ (CD45.2+),
and syngeneic CByJ.SJL(B6)-Ptprca/J (CD45.1+) as well as WT
C57BL/6J and syngeneic B6.SJL-Ptprca Pep3b/BoyJ (CD45.1+), WT
DBA/2J, and FVB/NJ mice were purchased from the Jackson Laboratory. The knockout strains C.129S2(B6)-Cxcr2tm1Mwm/J (CXCR2KO, BALB/cJ background), B6.FVB(Cg)-Mmp9tm1Tvu/J (MMP9-KO,
C57BL/6J background), FVB.Cg-Mmp9tm1Tvu/J (MMP9-KO, FVB/
NJ background), B6.129S7-Itgaltm1Bll/J (CD11a-KO, C57BL/6J background), and B6.129S4-Itgamtm1Myd/J (CD11b-KO, C57BL/6J background) were also obtained from Jackson Laboratory. Endothelialspecific CXCR2 ablated mice were generated by crossing C57BL/6Cxcr2tm1Rmra/J (CXCR2fl/fl, Jackson Laboratory) and B6;129-Tg
(Cdh5-cre)1Spe/J (Cdh5Cre, Jackson Laboratory) mice. Mobilization
experiments were performed with Cxcr2fl/flCre+ mice (CXCR2fl/WTCre+
were used as controls) reconstituted with WT BM from syngeneic
B6.SJL-Ptprca Pep3b/BoyJ (CD45.1+, Jackson Laboratory) donors. Following lethal irradiation (1× 9.5–11 Gy, using a cesium source) and
transplantation, mice were kept on 0.5 mg/ml sulfamethoxazole
and 0.1 mg/ml trimethoprim (HI-Tech Pharmacal), administered by
mouth in drinking water.
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Cell and tissue preparation
Peripheral blood (PB) and BM cells were recovered as previously
described (12). Cell counts (WBC) were measured on an automatic
hemocytometer (Hemavet 950, Drew Scientific). Total counts (per
tissue) as well as the majority of functional analysis were performed
with filtered and otherwise unmanipulated cell suspensions, whereas
red cells were removed from suspensions prepared for flow cytometry using hypotonic lysis. Absolute numbers of immunophenotypically defined populations (e.g., LSK cells) were calculated assuming CD45+ cells are equivalent to WBC from the corresponding
cell count analysis.
In vivo reagents and treatments
Human recombinant truncated Gro-ȕ peptide (tGro-ȕ, CXCL2,
SB-251353 from GlaxoSmithKline) was used for all in vivo experiments. Stock solution stored at –80°C was freshly thawed and diluted
immediately prior to the s.c. injection (2.5 mg/kg) (52). Murine
recombinant CXCL1 (PeproTech) and human recombinant CXCL8
(aa 23-99, Sino Biological) stock solutions were prepared in water.
All chemokines were diluted in PBS (GE Healthcare Life Sciences) or used directly in the CWHM-823 solution. CWHM-823 plus
chemokine mixtures were sonicated in a water bath for 15–30 minutes prior to injection to counteract precipitation. Firategrast was
synthesized based on the published structure (C27H27F2NO6; patent
no. US2014051655), dissolved in a 1% ethanol solution in PBS and
injected i.v. or s.c. (100 mg/kg). Mice treated with firategrast plus
tGro-ȕ received 2 separate injections. All other VLA4 antagonists,
BIO5192 (TOCRIS, Bio-Techne Corporation) (28), CWHM-842,
-822, -823, -824, and -825 were dissolved in DMSO (100× stock
solution) and diluted in NaHCO3/NaCl buffer (1:1, 10 mM NaHCO3,
pH 8; 0.9% wt/vol NaCl) for subsequent i.v., s.c. (CWHM-823 only),
or i.p. (CWHM-823 only) injection at 3 mg/kg. BIO5192 plus tGro-ȕ
and CWHM-842 plus tGro-ȕ treatment consisted of 2 separate
injections, whereas CWHM-823 plus Gro-ȕ was administered either
as 2 injections (VLA4 antagonist i.v., tGro-ȕ s.c.) or as one injection (i.v., i.p., or s.c.) as specified for each experiment. AMD3100
(Mozobil, Genzyme) suspension was prepared in PBS and administered s.c. (5 mg/kg). AMD3100 plus tGro-ȕ mixture was prepared
by diluting tGro-ȕ in the AMD3100 solution and then s.c. injected.
RhG-CSF (Neupogen, Filgrastim, Amgen) diluted in PBS was
injected i.p. every 12 hours at a dose of 100 ȝg/kg for a total of 4
(day 3) or 9 (day 5) doses. Broad spectrum matrix metalloprotease
inhibitor batimastat (BB-94, APExBio) was dissolved in DMSO,
diluted in corn oil (Sigma-Aldrich), vortexed thoroughly, and injected i.p. 12 and 2 hours (25 mg/kg) prior to the mobilization treatment. Control mice received DMSO/corn oil injections. In all other
experiments, mice injected with PBS, PBS/DMSO, or left untreated
(baseline) at the time point of analysis are referred to as control
animals throughout the manuscript.
Depletion of granulocytes
To deplete granulocytes in vivo the anti-mouse Ly6G/Ly6C antibody (Gr1, clone RB6-8C5, BioXCell) was administered i.v. (200 ȝg/
mouse) 36 hours prior to the mobilization treatment. Control mice
were treated with an isotype control antibody (clone 2A3, BioXCell).
Efficient depletion of peripheral blood granulocytes was confirmed
using differential blood count as well as flow cytometric analysis.

Induction of diabetes
Diabetes was induced in 8-week-old BALB/cJ mice by a single i.p. injection of 200 mg/kg streptozotocin (SZT, EMD Millipore) dissolved
in citrate buffer (pH 4.7–5.3, Sigma-Aldrich). Blood glucose levels
were measured with a portable blood glucose meter (Glucocard Vital,
ARKRAY USA Inc.). Animals with glucose values higher than 300 mg/dl
were used for mobilization experiments 2–3 weeks after SZT injection.
Transplantation
Serial competitive transplantation. Lethally irradiated CD45.2+ BALB/cJ
hosts received i.v. transplants consisting of 2.5 × 105 CD45.2+ BM cells
and a small volume (10 ȝl) of differentially mobilized blood (BALB/cJ
CD45.1+: G-CSF for 5 days vs. tGro-ȕ vs. VLA4 antagonist firategrast
or CWHM-823 vs. VLA4 antagonist plus tGro-ȕ). Twenty weeks after
the transplantation, PB composition of the recipients was analyzed for
the presence of blood graft–derived hematopoiesis (i.e. percent contribution of blood donor CD45.1+ cells within the CD45+CD3– compartment). Following PB analysis, BM cells of the primary recipients
were isolated and pooled based on WBC counts at equal proportion
per recipient per group (G-CSF and both VLA4 antagonist plus tGro-ȕ
groups). Primary recipient BM cell mixture (2.5 × 106 per mouse) was
injected into lethally irradiated secondary recipients (CD45.2+). PB
analysis of secondary hosts was performed 18 weeks after the transplantation. Similarly, CD45.1+ percentage within the CD45+CD3– fraction was determined.
Generation of transplantation chimeras for mobilization. To generate
hematopoietic specific CXCR2-KO mice, 1 × 106 BM cells from CXCR2KO animals (CD45.2+) were transplanted into lethally irradiated WT
syngeneic BALB/cJ CD45.1+ recipients. Control group of CD45.1+ hosts
received WT CD45.2+ BM cells. Conversely, stromal-specific knockouts were generated by transplanting lethally irradiated CXCR2-KO
animals with 1 × 106 CD45.1+ WT BM cells. In the corresponding control group, WT CD45.2+ hosts received CD45.1+ BM grafts.
For EC-specific CXCR2 ablation, lethally irradiated CXCR2fl/fl
Cdh5Cre+ hosts (C57BL/6 background, CD45.2+) were reconstituted
with syngeneic WT CD45.1+ BM (3 × 106 cells per recipient). In the
control group CXCR2fl/WTCre+ and CXCR2WT/WT Cre+ mice were used
as recipients.
Mobilization studies in chimeric animals were started 8–12 weeks
after the transplantation. Lack of contribution of recipient endogenous hematopoiesis was verified by flow cytometry in each recipient.
Fluorescence activated cell analysis and sorting (FACS)
Cell labeling was performed according to standard protocols using
established marker panels for identification of different subsets
in mouse hematopoietic tissues as previously described (10, 12).
Lineage-negative and c-Kit–positive (Lin– kit+) or lineage-negative,
Sca-1–positive and c-Kit–positive cells (LSK cells) were an estimate
for HSPCs, whereas HSCs were identified as LSK SLAM (LSK CD150+
CD48 –) cells. Antibodies used in this study are listed in Supplemental Table 6. Sample acquisition was performed on Gallios (Beckman
Coulter Life Sciences) and BD LSRFortessa (BD Biosciences) flow
cytometers or BD FACS Aria II cell sorter (BD Biosciences). Data
were further analyzed using FlowJo software (Tree Star) or FACSDiva software (BD Biosciences). Cell isolation by flow sorting was
performed on BD FACS Aria II. Cell-cycle analysis was performed as
previously described (10, 12).
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Colony-forming unit assay
Cells were incubated in duplicate in commercially available growth
factor supplemented with methylcellulose medium for mouse
CFU-Cs (Stem Cell Technologies or R&D Systems) as described (10,
12). CFU-Cs (BFU-E, CFU-GM, and CFU-GEMM) were enumerated
after 6–8 days of culture.
Quantitative real-time PCR
For analysis of gene expression in cell populations (LSK, LSK SLAM,
and different mature cell fractions) sorted from the BM RNA was
isolated using RNA XS column kit (Machery-Nagel). Ambion Turbo
DNA-free Kit (Thermo Fisher Scientific) was then used to remove
genomic DNA followed by reverse transcription of the RNA using the
QuantiTect Reverse Transcription Kit (Qiagen). qRT-PCR (Cxcr2 and
Gapdh) was performed using TaqMan Master Mix, probes and primers
(Applied Biosystems) listed in Supplemental Table 7.
Microarray analysis
RNA from LSK cells sorted from untreated BM or PB of differentially mobilized (G-CSF [5 days], AMD3100, or CWHM-823 plus
Gro-ȕ; single injection) mice was prepared using the RNA XS column
kit (Macherey-Nagel) and hybridized to the Mouse Gene Expression v2 4×44K microarray (Agilent Technologies). Normalization
and quality assessment of expression data were performed using
Partek Genomic Suite (Partek Inc.). Thus, log2 scale-transformed
and filtered expression data were used for PCA plot generation.
Hierarchical clustering was performed using the top 1000 differentially (significance) regulated genes. All original microarray data
were deposited in the NCBI’s Gene Expression Omnibus database
(GSE123505) and expression data can be accessed at https://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE123505.
Pharmacokinetics
PB was drawn from the facial vein without anesthesia and collected
into lithium heparin anticoagulated tubes (Sarstedt AG & Co).
If not processed immediately, samples were stored on ice (approximately 1 hour). After centrifugation (25 minutes, 800–1500g, 4°C)
plasma supernatant was carefully removed, frozen, and stored
at –80°C until just before analysis. Plasma samples or standards
prepared in plasma matrix (50 ȝl) were added to a 96-well plate.
To each well, 200 ȝl cold acetonitrile containing 100 ng/ml
extraction internal standard enalapril was added. The plate was
vor texed for 5 minutes, and then centrifuged at 1600g for 5 minutes at 4°C. The supernatant (200 ȝl) was transferred to a second
96-well plate, evaporated to dryness under nitrogen, reconstituted
with 100 ȝl of 0.1% vol/vol formic acid in 9:1 water/acetonitrile,
vortexed for 5 minutes, and the samples were analyzed by LC/
MS. CWHM-823 concentrations were determined on a Sciex
API-4000 LC/MS system (SCIEX) in positive electrospray mode.
Analytes were eluted from an Armor C18 reverse phase column
(2.1 × 30 mm, 5 ȝm) using a 0.1% formic acid mobile phase system
with aqueous to acetonitrile gradient over 3.7 minutes at a flow rate
of 0.35 ml/min. Peak areas for the mass transition of m/z 518 > 472
for CWHM-823 and m/z 376 > 91 for enalapril (IS) were integrated
using Analyst 1.5.1 software. Peak area ratios of CWHM-823 area/
enalapril area were plotted against standard concentrations with a
1/x-weighted linear regression.
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Water solubility assay
For each VLA4 antagonist tested, 1–2 mg solid compound was placed
in an Eppendorf tube with 1 ml equilibrium solubility buffer (ESB, 50
mM citric acid, 50 mM K2HPO4, 50 mM Ammediol, and 50 mM KCl,
pH 7) and incubated in a Thermomixer for 48 hours at 25°C at 500 rpm.
After 24 hours, tubes were centrifuged at 3000g for 5 minutes, and an
aliquot of the supernatant was removed and diluted into linear standard range of the standard curve for the LCMS method. Sample dilutions and standards were made in 75:25 ESB/acetonitrile. Firategrast,
BIO5192, CWHM-823, CWHM-824, CWHM-825, and CWHM-842
concentrations were determined on a Sciex API-4000 LC/MS system
(SCIEX) in positive electrospray mode. Analytes were eluted from an
Armor C18 reverse phase column (2.1 × 30 mm, 5 ȝm) using a 0.1%
formic acid mobile phase system with aqueous to acetonitrile gradient
over 3.7 minutes at a flow rate of 0.35 ml/min. Peak areas for the mass
transition of m/z 500.3 > 454.2 for firategrast, m/z 817.2 > 394.0 for
BIO5192, m/z 505.0 > 176.0 for CWHM-822, m/z 518.0 > 472.2 for
CWHM-823, m/z 621.2 > 575.0 for CWHM-824, m/z 474.6 > 192.2 for
CWHM-825, and m/z 523.4 > 390.2 for CWHM-842 were integrated
using Analyst 1.5.1 software (SCIEX). Peak areas were plotted against
standard concentrations with a 1/x-weighted linear regression.
VCAM1 binding assay
G2 ALL cells (1.5 × 105 cells per sample, The Hospital for Sick Children)
were incubated with increasing concentrations of the different VLA4
antagonists for 30 minutes at room temperature (RT). Subsequently,
human recombinant VCAM1/Fc chimera protein (R&D Systems) was
added to the samples at a final concentration of 10 ȝg/ml. After a second 30-minute incubation step at RT, cells were washed twice with
HBSS/0.1% BSA buffer and secondary antibody (PE-labeled donkey
anti-human IgG, catalog 709-116-098, Jackson Immunoresearch Laboratories) added at 1:100 dilution. Control samples were stained with
PE-labeled donkey IgG (catalog 017-110-006, Jackson Immunoresearch Laboratories, 1:100 dilution). Secondary antibody staining was
performed at RT for 30 minutes. Following addition of 7-AAD for 5
minutes at RT, cells were washed twice with HBSS/BSA buffer and
analyzed by flow cytometry.
Integrin binding assay
The potency of compounds in blocking ligand binding to integrins
a4b1 and a4b7 was determined by modification of our previously
described methods (71). Briefly, purified human VCAM1 (R&D
Systems) diluted to 5 ȝg/ml in TBS+ buffer (25 mM Tris pH 7.4, 137
mM NaCl, 2.7 mM KCl, 1mM CaCl2, 1 mM MgCl2, 1 mM MnCl2) was
added to wells of a 96-well transparent microtiter plate and incubated overnight at 4°C. Wells were washed 3 times with TBS+ and
blocking buffer (TBS+ with 1% bovine serum albumin), the plate was
incubated for 1 hour at 37°C, and then washed 3 times with TBS+
buffer. Recombinant human integrin ITGA4/ITGB1 (Į4ȕ1; VLA4)
or ITGA4/ITGB7 (Į4ȕ7) (R&D Systems) was diluted to 1 ȝg/ml in
TBS+/0.1% bovine serum albumin. Test compounds were diluted
into the integrin solution and added to the washed ligand-coated
plate according to a standard template with each sample repeated in triplicate. After incubation for 2 hours at room temperature,
the plate was washed 3 times with 150 ȝl TBS+ buffer. To each well,
biotinylated anti-ȕ1 (catalog BAF1778, R&D Systems) or anti-Į4
antibody (clone 7.2R, R&D Systems) at 1 ȝg/ml in TBS+/0.1% BSA
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was added and the plate covered and incubated for 1 hour at RT.
After washing the plate 3 times with TBS+ buffer, streptavidinconjugated horseradish peroxidase (R&D Systems) diluted in TBS+
blocking buffer was added to the wells and the plate incubated for
20 minutes at room temperature. The plate was washed 3 times
with TBS+ buffer followed by addition of 50 ȝl TMB substrate
(MilliporeSigma). After incubation for 20 minutes at RT, plates were
read by colorimetric detection at 650 nm wavelength using a Tecan
Safire II plate reader. Concentration-response curves were constructed by nonlinear regression (best fit) analysis, and IC50 values
were calculated for each compound.
To evaluate the broader selectivity of test compounds, potency
against a nontargeted beta-1 subunit–containing integrin, ITGA2/
ITGB1 (Į2ȕ1), was measured as previously described (71). Assessment of compound potency against 2 selected members of the
RGD-binding integrin family, ITGA5/ITGB1 (Į5ȕ1) and ITGAV/
ITGB3 (Įvȕ3), was determined by a similar method in which binding of the purified human integrins (R&D Systems) was assessed
to plates coated with their respective purified ligands, human
fibronectin (2 ȝg/ml, R&D Systems) and human vitronectin (1 ȝg/
ml; R&D Systems). Biotinylated anti-ITGAV (Įv) or anti-ITGA5
(Į5; R&D Systems) antibodies were used to detect the stably bound
integrins in conjunction with streptavidin-conjugated horseradish
peroxidase as described above. The Įvȕ3 and Į5ȕ1 assays were validated by inclusion of a known potent inhibitor of these integrins,
CWHM-12 (71), while the Į2ȕ1 assay was validated by inclusion
of another previously described inhibitor, compound 8 (data not
shown) (72).

Specificity screening
tGro-ȕ was sent out to DiscoverX (DiscoverX Corporation) for blinded
profiling against the gpcrMAX panel (148 G protein–coupled receptors
screened in both, agonist and antagonist mode) using the PathHunter
beta-arrestin enzyme fragmentation (EFC) technology.
Statistics
Data are mean ± SEM unless indicated otherwise. Linear mixed
models were used to analyze experiments with data repeatedly
measured from the same mice, while analysis of variance (ANOVA)
was used for data from independent samples. A logarithm transformation was performed as necessary to better satisfy the normality
and homoscedasticity assumptions (see Figure legends for details).
Ad-hoc multiple comparisons were also used for between-group differences of interest. The resultant P values were adjusted by Holm’s
step-down Bonferroni’s adjustment. Compared with the widely used
Bonferroni’s adjustment, a step-down method is more powerful
(smaller adjusted P values) while maintaining strong control of the
familywise error rate. All analyses were 2-sided and significance was
set at a P value of 0.05. The statistical analyses were performed using
SAS 9.4 (SAS Institutes).
Study approval
All animals were housed at the Washington University Medical School
vivarium under SPF conditions with autoclaved chow and water ad
libitum. All experiments were performed in accordance with the
guidelines of the Washington University Animal Studies Committee,
approved by the IACUC in agreement with AAALAC guidelines.
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